Pace of BMS cancer trial leaves investors wary

Forget that Bristol-Myers Squibb ($BMY) beat analyst expectations for both profits and revenue Friday. Shareholders were focused on nivolumab, a cancer immunotherapy currently in development. So when BMS said it would continue its mid-stage instead of diving into a late-stage program testing it with melanoma hit Yervoy, investors feared it could mean problems with the combo--and sent shares down nearly 6%. More